← Evidence map

ArticlePloS one2017

Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy.

Ryota Horibe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

10 papers cite it

2017

2018

2019

2020

2021

2022

2023

this papercites it

Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy. | OpenQuestion